HOUSTON, Texas – October 2002 – Cell>Point L.L.C. is preparing to commence clinical biokinetic and biodistribution studies at The University of Texas M.D. Anderson Cancer Center on 99mTc-EC-Metronidazole, 99mTc-EC-Annexin V and 99mTc-EC-Cox-2. If results from the studies are as expected, Cell>Point will prepare and submit IND applications with the FDA for the three “kit” compounds. 99mTc-EC-Metronidazole will be studied as a tumor hypoxia marker, 99mTc-EC-Annexin V will be studied as a programmed cell death marker and 99mTc-EC-Cox-2 will be studied as a tumor marker.
Cell>Point is also preparing to commence clinical biokinetic and biodistribution studies on 99mTc-EC-Deoxyglucose for lymphoma. If results from the study are as expected, Cell>Point will prepare and submit an amendment to its 99mTc-EC-Deoxyglucose IND (63,698) to include lymphoma as an additional indication.